Atlas Trials

Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer

Clinical trial NCT05479240 · NOT_YET_RECRUITING

Trial details

NCT number
NCT05479240
Sponsor
Fujian Cancer Hospital
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Immunotherapy
Start date
2023-09-01
Primary completion
2025-06-01
Enrollment
94

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.